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ABSTRACT 
It has been proposed, based on the theory of complex gene regulatory networks, that cell 
types, including cancer cells, represent attractor states of the network dynamics. In this study, 
we proposed an Epstein - Barr virus (EBV) latency I to latency III switch model. Exploiting 
this EBV latency switch model, we characterized for the first time the detailed dynamics of a 
cancer cell attractor at single-cell-resolution and found that the edge cells from a non-
malignant cell line could transiently and stochastically adopt some malignant characteristics 
due to biological noise. This work might impact design of future rational cancer therapies by 
taking into account the dynamic robustness and high volatility of a heterogeneous cancer cell 
population. We also evaluated the impact of EBV load as a biomarker for hematopoietic stem 
cell transplantation (HSCT) patients. 
We established and validated a latency I to latency III switch model that is based on on-off 
status of the EBV C promoter during latent infection by competition between EBNA1 and 
Oct proteins together with co-regulators (Paper I). 
The dynamics of gene expression space, owing to a balance between homeostatic forces and 
stochastic fluctuations, has led to the cancer cell attractor conceptual model. Using the 
immortalized and malignant carrying EBV B-cell lines, we characterized the detailed 
structure of cell attractors. Any subpopulation selected from a population of cells repopulated 
the whole original basin of attraction within days to weeks. Cells at the basin edges were 
unstable and prone to apoptosis. Cells continuously changed states within their own attractor, 
thus driving the repopulation. Perturbations of key regulatory genes induced a jump to a 
nearby attractor. Using the Fokker-Planck equation, this cell population behavior could be 
described as two virtual, opposing influences on the cells: one attracting towards the center 
and the other promoting diffusion in state space. Transcriptome analysis suggests that these 
forces result from high-dimensional dynamics of the gene regulatory network. The clonal cell 
population heterogeneity was investigated by single cell RNA sequencing method. We 
sequenced different subpopulations within the clonal cell populations and found that edge 
cells from the non-malignant cell line (non-malignant attractor), represent a distinct 
population more close to the malignant attractor. This was based on mRNA expression 
pattern, single cell imaging, clustering analysis, and functional studies. We propose that these 
findings can be generalized to all cancer cell populations and represented intrinsic behaviors 
of tumors, offering new perspectives in the study of cancer. The results provide quantitative 
knowledge on non-genetic intercellular heterogeneity and its dynamics within an isogenic cell 
population of cancerous cells, affording insights at a new level of resolution, between 
molecular pathways and macroscopic tumor behaviors (Paper II and III). 
We evaluated the impact of EBV load on survival of 51 HSCT patients. Patients with very 
high or very low level of cell bound EBV-DNA levels had a shorter overall survival (OS) 
than those with moderate EBV load: OS at 5 years was 67% vs 90%, (P < 0.03). There was a 
conspicuous relationship between EBV load and the dynamics of reconstitution of total and 
EBV-specific T cells in a few patients. According to multivariate analysis, two other factors 
were also associated to early mortality:  acute GVHD II-IV (p<0.02) and pre-transplant 
conditioning with total body irradiation (TBI) ≥6 Gy (p<0.03). All patients showing these 
three criteria died within two years after transplantation. This points to a subgroup of HSCT 
patients which deserve special attention aiming to improve their future treatment (Paper IV).  
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1 INTRODUCTION 
1.1 Brief overview of cancer 
1.1.1 Cancer epidemiology and challenges in cancer therapy 
The original meaning of the word “cancer” is crab. This was based on the 
observation that conspicuous blood vessels feed the tumors and resemble the 
claws of a crab (1, 2).   Hippocrates first used the term Karkinos for a swelling 
or ulcerous formation, even hemorrhoids, whereas he used karkinoma for non-
healing “cancer”.  
Paleopathologic findings have demonstrated cancers already in animals of 
prehistoric times (3). The earliest known written description of cancer  (a breast 
cancer) is from 3000 BC and was  discovered in the Edwin Smith Papyrus (3). 
The Egyptians attempted to treat cancer with cautery, knives, salts, arsenic 
paste, and the Chinese attempted herbal remedies already more than 3000 years 
ago. Indians, Persians, Sumerians, and Hebrews also made early attempts to 
cure the cancer during the same period (3).  
Although the long history with big efforts to understand and cure cancer, there 
are still major obstacles to achieve the goal and thus cancer is still a major 
challenge to public health. Cancer is a leading cause of death worldwide and 
this burden is expected to increase (4). In 2012, there were estimated 14.1 
million new cancer cases and 8.2 million deaths of cancer worldwide 
(excluding non-melanoma skin cancers) (4). Breast and lung cancer show the 
highest incidence and mortality worldwide in women and men, respectively (4). 
Other frequently diagnosed cancers in women are those of colon and rectum, 
cervix and corpus uteri, stomach, ovary, thyroid, liver and non-Hodgkin 
lymphoma. The most common in men are those of prostate, colon and rectum, 
stomach, liver, esophagus, bladder, non-Hodgkin lymphoma, kidney and 
leukemia (Figure 1). The most common and lethal types of cancer differ 
between economically developed and developing countries, between gender, 
races and age. The estimated economic cost of cancer to society was 
approximately 1.16 trillion US dollar in 2010(5) excluding the substantial long-
term costs for care-givers and families. 
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Figure 1. Estimated age-standardised incidence and mortality rates in men, women and both 
sexes worldwide, 2012. Source: GLOBOCAN 2012. 
(http://globocan.iarc.fr/Pages/fact_sheets_population.aspx) 
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During the last decades, the understanding of cancer has improved remarkably 
and a valuable body of knowledge of cancer biology has been built. However, 
several key features of tumors biology, such as intra-tumor heterogeneity, and 
therapy resistance are still controversial, while the understanding of 
tumorigenesis and tumor progression is incomplete. Although some success 
stories, cancer treatment is still inefficient. The global annual costs for cancer 
drugs was approximately 49 billon US dollars in 2011, of which $ 37 billion 
was linked to treatments resulting in adverse side effects without therapeutic 
benefit to patients (6). Cancer treatment and care are so expensive that not only 
developing countries, but also the developed countries, will struggle to manage 
the spiraling costs  (5).  
In summary, in spite of the major attempts to understand and cure cancer , the 
economic burden for and relative failures of cancer therapy, makes cancer one 
of  the major challenges in public health, as well as a  life-threatening disease to 
individual patient.  
 
1.1.2 The current view of cancer biology 
1.1.2.1 Hallmarks of cancer 
Hanahan and Weinberg summarized the most common features or “programs” 
affected in cells undergoing tumorigenesis as the eight hallmarks and two 
enabling characteristics of cancer : sustaining proliferative signaling, resisting 
cell death, evading growth suppressors, enabling replicative immortality, 
inducing angiogenesis, avoiding immune destruction, deregulating cellular 
energetics, activating invasion and metastasis; acquiring genome instability and 
mutations, tumor promoting inflammation (Figure 2) (7). Currently new drugs 
are being developed to target each of the hallmarks and enabling 
characteristics(7).  
 4 
 
 
Figure 2. Eight hallmarks,  two enabling characteristics of cancer and their corresponding 
targeting therapeutics (7).  
1.1.2.2 Models of tumorigenesis and their challenges  
Tumorigenesis is prevailingly understood as a multistep process driven by a 
sequence of irreversible genetic alterations, each conferring one or another type 
of survival and growth advantage, resulting in progressive transformation of 
normal cells into cancer cells. The process is thought to follow a Darwinian 
evolutionary process at the cell population level (8, 9). This is a DNA centric 
paradigm, in which the tumor suppressor genes and oncogenes play the crucial 
role. These key genetic aberrations are the main focus of current cancer drug 
development.  
In line with this Darwinian evolutionary theory, (intra-)tumor heterogeneity is 
explained by different models, including the clonal evolution model (8) due to 
genetic and/or epigenetic events (2) and/or by the cancer progenitor/stem cell 
model.  
1.1.2.2.1 The clonal evolution model 
According to the clonal evolution model, mutations of genes starting in normal 
cells occur randomly and accumulate over time. Alterations which provide 
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advantages for survival and  growth make such cells expand to compete out 
non-affected cells, and  other cancer hallmarks as defined by Hanahan and 
Weinberg, are subsequently acquired (7, 9). By parallel selection more than one 
neoplastic subclone will be established (Figure 3). 
 
  
Figure 3. The clonal genetic model of cancer(2).  ONC: dominantly acting oncogenes. TSG: 
tumor suppressor genes. 
However, the mutation rate of a specific gene is so low, due to the efficient 
controls - the DNA repair system and the checkpoints in mitosis – so that the 
accumulation of mutations is inefficient. It is unlikely that all the mutations 
required from tumor initiation, to invasion and metastasis could be acquired 
during a human life span(10). To circumvent this problem, two concepts have 
been introduced: genome instability and clonal cooperation.  
Genome instability enables and accelerates the evolution of subcolones to 
acquire the hallmarks of cancer (9). Mutations of key guardians of the genome, 
e.g., p53, is one cause of acquired genome instability and contributes to  the 
mutator phenotype in cancer (10). According to the clonal cooperation model, 
cells of subclones interact with each other.  While most of such interactions are 
neutral, positive interactions result in mutual benefits between cells by sharing 
hallmark properties and accelerating tumor progression by the Darwinian 
selection force (11, 12). 
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The intra-tumor heterogeneity is then explained by the genetic variation 
between the selected subclones. Cancer therapy can often only target some of 
the mutations, i.e., there are subclones with acquired resistant mutations or 
preexisting resistance, which cause failure of therapy.  
Colon cancer is the prime illustration of this model (Figure 4). Vogelstein et al 
established the first linear progression scheme for colon cancer, based on 
familial polypus colon cancer (APC). During progression of colon cancer, 
phenotypic changes mirror the genetic (and also epigenetic) aberrations and the 
continued process follows a  predictable order, starting with  the loss of 
(adenomatous polyposis coli) APC, locus specific DNA hypomethylation, 
mutation and  activation of K-ras, loss of a tumor suppressor gene in 
chromosome 18q and  loss of p53. At the phenotypic level the normal 
epithelium becomes hyperplastic, then small benign adenomas appears, which 
develops into carcinoma, and eventually become invasive and metastatic (11-
13). However, it turns out that almost no cancers really follow such an idealized 
linear progression model, not even colon cancer. This paradigm suggests a 
linear deterministic process caused by genes controlling complex phenotypes 
and that somatic mutations are the main drivers of tumor development. 
However,  during the past ten years cell and tissue biology have undergone a 
revolution resulting  in that new or largely neglected phenomena have to be 
adopted in tumor biology, such as  epigenetic regulation, gene regulation by 
microRNAs, tumor cell heterogeneity including progenitor cells, the 
microenvironment including inflammatory processes and the rediscovery of the 
Warburg effect. This has resulted in new tools for description of the molecular 
biology of tumors, but also in the discovery of a much larger complexity than 
earlier anticipated.  
 
Figure 4. Linear progression scheme for colon cancer (APC). Adapted from ‘the biology of 
cancer’(14).  
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There are limitations of this model: 
1. The Darwinian evolutionary selection is based on phenotype, not genotype. 
The alterations in a gene do not necessarily cause phenotypic changes. Thus a 
phenotypic change does not strictly correspond to one specific event in the 
genome. Thus, there is no 1:1 correspondence between genotype and 
phenotype.   
For example, even in the best defined and original example of this model, 
hereditary colon cancer, no common mutations responsible for development of 
invasion and metastasis have been identified. Thus some specific changes in 
gene expression has  no underlying mutation resulting in invasion and 
metastasis (2).  
2. In spite of  the big amount of knowledge acquired on suppressor genes and 
oncogenes and on their signaling pathways, modern cancer drug development 
aiming at restoring mutated key gene functions to eliminate the tumor has not 
been convincingly successful, with an efficacy rate below 25% (15).   
This linear paradigm seems to be an oversimplified view assuming that 
targeting some of the most important mutated genes can eliminate all the  
cancer cells, while ignoring gene expression stochasticity and gene regulatory 
networks involved. 
1.1.2.2.2 The epigenetic clonal and epigenetic progenitor model 
The epigenetic clonal model also follows a Darwinian evolutionary process (2). 
It is not in conflict with the clonal evolutionary model, but adds one more 
dimension to that model. In this model, epigenetic alterations could be 
surrogates for genetic changes, i.e., tumor suppressor gene could be silenced by 
epigenetic control rather than mutation, and oncogenes could be deregulated by 
epigenetic mechanisms as well. This can result in chromosomal instability and 
loss of imprinting, like classical mutations do, which also follows a Darwinian 
evolutionary process (2) (Figure 5).  
The key difference between epigenetic and genetic mechanisms in 
tumorigenesis is that epigenetic alterations are reversible while genetic 
mutations are not (16). However, reversible epigenetic changes can serve as a 
substitute for irreversible genetic changes. As an example a treatment that 
reduced the level of heat shock protein 90 (HSP 90) caused morphological 
defects in flies when genetic modifications were strictly blocked and epigenetic 
alterations could be clearly confirmed (17, 18).  
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Figure 5. The epigenetic progenitor model of cancer (2). ONC: dominantly acting 
oncogenes. TSG: tumor suppressor genes. TPG: tumor-progenitor genes. GKM: gatekeeper 
mutation. 
The epigenetic clonal model can also explain a large part of intra-tumor 
heterogeneity and therapy resistance, due to epigenetic variation in genome 
control (19). 
A special case is the epigenetic progenitor model suggested by Feinberg et al, 
namely the first event in tumorigenesis are epigenetic due to perturbations in the 
local environment, instead of mutations(2). In fact it has been demonstrated that 
in rare tumors all the tumorigenic mechanisms are epigenetic, without any 
genetic mutations, like in ependymomas (20, 21). 
Thus epigenetics can be involved at three levels of tumorigenesis: 1. Epigenetic 
reprogramming to cancer progenitor cells. 2. In subclonal evolution playing a 
similar role as mutations. 3. Generate epigenetic plasticity and heterogeneity 
within tumors(2).  
1.1.2.2.3 The cancer progenitor/stem cell model 
The concept and definition of cancer stem cells (CSC) is still controversial (22-
27).  The concept of stem cell is well established and clear. It refers to cells with 
pluripotent capacity to differentiate into cell types which comprise each organ 
and with the simultaneous ability to perpetuate themselves through self-renewal 
(27, 28).  The differentiation of tissue specific stem cells is highly restricted to 
cell types within a specific organ,  compared to the embryonic stem cells which 
are totipotent(28).  
The idea that tumors might arise from a rare  population of cells with stem cell-
like properties was proposed about 150 years ago (28). The cancer stem cell 
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model posits that tumors are hierarchically organized including a small 
population of cells with the ability to seed new tumors and to spawn non-CSC 
populations lacking tumor initiating ability(Figure 6) (22, 23). CSCs express 
certain stem cell markers.  In the CSC model, a small usually quiescent 
subpopulation of tumor cells-the CSCs- differentiate asymmetrically and 
generate both more tumor initiating CSC cells and non-tumor initiating cells. 
Great efforts have been made to identify specific CSC markers for a particular 
type of tumor. In some malignancies, such markers have been reported and 
validated (29, 30).  
 
Figure 6.  Cancer stem cell model. Adapted from (27).  
Intra-tumor heterogeneity according to the CSC model is explained by 
asymmetric cell division and the ability to generate phenotypically and 
functionally different down-stream cell generations to the CSCs. CSCs are 
quiescent or slow proliferating cells. During systemic treatment they might 
therefore show a weak response to genotoxic damage and give rise to an even 
more malignant subpopulation of tumor cells during relapse. Once the selective 
pressure is withdrawn, the relatively therapy resistant CSCs would feed a new 
tumor (31-33).  
The key concern about the CSC model is if such a differentiation hierarchy of 
CSCs is necessary for tumorigenesis. Although there are several examples 
which conform to the CSC model (30, 34), there is also good evidence that 
some types of tumors are not hierarchically organized and that the phenotypic 
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heterogeneity of the tumorigenic cells can be reversible (22, 35). This is a 
challenge to the CSC model. To pay tribute to caution, the term “cancer stem 
cell-like” has been applied recently.  
In the model we have explored, the cancer attractor model, we found that the 
edge cells, which are at the extreme edge (in relation to a specific 
predetermined marker) of the basin of the attractor, showed slow, or even no 
proliferation. These cells are transiently at the edge, which means they would be 
able to leave this extreme state and acquire normal proliferation capacity once 
they are not at the edge any more. Thus we can conclude that a temporarily 
existing dormant and phenotypically different subpopulation of tumor cells does 
not necessarily have to be a product of a hierarchical organization, but can also 
arise due to biological noise and to variations in the gene regulatory network 
(36-39). 
 
1.2 Cell attractor 
Although efforts have been made to adapt the current “modern” cancer 
paradigm to the insights about complexity in cell and tissue biology, it is now 
more of a repair patchwork than a model with an integrated perspective (7, 9). 
The entry of tumor biology into the realm of complex (cellular) systems can not 
be neglected any more. It will be necessary to find new, additional novel 
approaches to understand cancer processes in order to improve clinical 
developments. This is a major challenge, as the science of complex system is 
lagging in providing useful models and tools. Even the scientific nomenclature 
and the definitions in this field of science are insufficiently developed.¨ 
 
1.2.1 Origin of the idea 
Max Delbrück first pointed out in 1949 that ‘many systems in flux equilibrium 
are capable of several different equilibria under identical conditions. They can 
pass from one state to another under the influence of transient perturbations’ 
(40, 41).  The ability of small gene regulatory circuits to produce more than one 
stable equilibrium state was also later proposed by Jacob and Monod, to explain 
that differentiation could result in a multitude of stable phenotypic states (42, 
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43). In the 1960s, Stuart Kauffman using Random Boolean Networks showed 
that when connected by Boolean functions, hundred thousands of mutually 
regulating genes would be able to establish hundreds of stable equilibrium state, 
termed attractors (44-46). Huang and Kauffman suggested that such an  
attractor would correspond to a gene expression pattern associated with a cell 
type (47). 
There is another cell regulatory model relating to phenotypes, designated the 
‘independent attractor’ model by Baverstock. It arises from ‘the interactions 
between active gene products (mainly proteins) and independently of the 
genomic sequence’(41). The difference between these two ‘attractor’ models 
has been discussed in detail by Baverstock (48). The ‘independent attractor’ 
model is still very hypothetical and its biological meaning still awaits further 
exploration and validation. In this thesis, the ‘independent attractor’ model will 
not be discussed further. 
 
1.2.2 The conceptual development  
Though it has been decades since the concept of cell attractors was originally 
proposed, the development of this field has been slow and the impact of the idea 
has had a low impact in cell biology and tumor biology.  Still at the stage of 
hypothesis, most of its applications have been based on in silico modelling 
while very few in vitro or in vivo experiments have been performed with the 
aim to explore and validate the theory. Most publications are reviews, opinions 
or perspectives while the original research papers are few. 
To explore whether it is helpful to view cells as biological attractors would be 
an important step in conceptual consolidation. For this purpose network 
attractors would be applied as an ideal model to describe fundamental principles 
governing cell behavior and the appearance and maintenance of distinct cell 
types. 
1.2.2.1 Boolean network  
Using Boolean networks, the activation states of individual genes are described 
by a simple "on-or-off" parameter and studied in computer simulations with 
varying complexity. Given a set of simple rules, one gene network can assume a 
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very large number of theoretical positions in its n-dimensional state-space 
coordinate system. Using the reduction of levels of gene expression to two 
states (on-off;1-0) as digitals in Boolean algebra simulations, the number of 
stable states (termed attractors) that the network  can assume is very limited, 
compared to the immense number of possibilities. This "conceptual model" 
represents fundamental and suggested features of the functionality of real gene 
regulatory networks.   
1.2.2.2 The gene regulatory network and the attractor  
A gene regulatory network (GRN) is established based on the fact that genes 
influences the expression of other genes through molecular regulatory 
interactions (49). It refers to a hard-wired architecture and is quite robust but 
might change as a consequence of mutations (47, 49). It is the wiring of the 
intracellular network that makes the system robust and compensates for the 
variations so that the cells can maintain their identity (cell type) and function in 
spite of the variations.     
The expression level of the genes changes over time, collectively manifested as 
the change of the gene expression patterns, which is referred to as ‘network 
dynamic’(49).  
Based on the GRN concept, an attractor is seen as a point in space of the n-
dimensional coordinate system to which objects in space seem to be attracted, 
where n is the total number of genes. An attractor of a GRN represents a virtual 
state of the expression level of all genes of a cell type. If there was no inter-
cellular heterogeneity, the cells of the same type would be in exactly the same 
point, the attractor. However, in reality data shows that most individual cells 
representing one cell type will not be positioned at the point of the attractor, but 
rather in a more or less distributed cloud around the attractor due to a 
conspicuous heterogeneity of gene expression levels (Figure 7).  The closer to 
the attractor, the higher density of cells there will be. The area of this cloud is 
designated the basin of attraction of the attractor. In this domain the gene 
network can operate in a relatively stable manner and is only perturbed by 
intrinsic fluctuations and responses to small, random external influences. In 
other positions the network is unstable.  All these basin of attractors constitute 
together a virtual landscape with valleys and ponds separated by hills and 
ridges. So an attractor is a stable gene network state and represents one type of 
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cells, and all these basin of attractors representing the different cell types 
constitute together the virtual landscape (36, 43).  
 
Figure 7.  A schematic representation of the cancer cell attractor model. 
 
1.2.2.3 The quasi-potential landscape, Waddington’s epigenetic landscape, 
and network entropy 
In the cell attractor model, each dimension in the n-dimensional space (n= 
number of genes in the genome) represents the expression level of one gene, 
respectively. Huang proposed that Waddington’s landscape is more than a 
metaphor by computing and interpreting the quasi-potential landscape, in which 
n dimensions have been compressed into two and the quasi-potential U has 
been introduced as one dimension, based on his demonstration that the relative 
stability of a network state could be computed and represented as a quasi-
potential energy U of each state S (49, 50). The combined quasi-potential 
landscape of basins of attractors have superficial similarities with Waddington’s 
epigenetic landscape suggested 60 years ago (Figure 8) (43, 51). 
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Figure 8. Waddington’s epigenetic landscape, attractor and differentiation. Adapted from 
Waddington, 1957(51). 
In the epigenetic landscape, pluripotent stem cells initially at the highest point 
in the landscape “roll down” though the valleys, to the bottom. This represents 
the development of the embryonic cells to the mature cell types. Development 
is the process when cells move to its ‘lowest energy’ attractors.  
Erwin Schrödinger described living systems as ‘feeding on negative 
entropy’(52).  It has been demonstrated that entropy rate decreases during the 
differentiation and the cellular network entropy could reflect the energy 
potential of a virtual biological landscape like Waddington’s differentiation 
landscape (53). 
1.2.2.4 The cancer cell attractor 
In this state space-landscape model of a gene network there might also be an 
unknown number of possible but normally unexploited positions. It has been 
suggested that such ‘illegitimate’ positions can be entered by cancer cells (43),  
hence the cancer cell attractor model. One ultimate question is whether cancer 
precursors can be derived from a normal heterogeneous cell population?  
Edge cells- those at the edge of the basin of the attractor - according to the 
conceptual model are transitory, unstable states, and will either quickly find one 
of the adjacent attractors or disintegrate resulting in cell death. The 
characteristics of the edge cells, including higher mortality and significantly 
slower proliferation of the edge cells has been validated (36).  We hypothesize 
that the edge cells may rarely be able to jump to a neighboring legitimate or 
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illegitimate attractor. The entering of a legitimate attractor results in cell type 
switch and to an illegitimate attractor results in tumor initiation. 
In the cell attractor model, mutations are suggested to change the GRN and 
affect the ‘height’ of the ridges between the valleys so that access to normally 
inaccessible attractors, including malignant cell attractors, can occur more 
easily(49). Thus, mutations would neither be a sufficient nor a necessary 
condition for tumor initiation, but by modifying the local landscape, they could 
promote or accelerate tumorigenesis.  
 
1.2.3 Potential applications of the cell attractor 
Besides being one novel model of tumorigenesis, the ‘cancer cell attractor 
model’ as discussed above, the cell attractor model can also be applied as a tool 
to study aspects of complexity in cell biology:  
1.2.3.1 The cell attractor as a tool to study cellular heterogeneity 
The same GRN, due to biological fluctuations and regulation between genes, 
can generate different transcriptomes(43, 49) which correspond to the different 
cellular phenotype (54).  
1.2.3.2 The cell attractor as a model for cell differentiation and cell 
phenotypic switch 
In the epigenetic landscape based on GRN, the pluripotent cell moves down 
along the valley (i.e., trajectory of differentiation) to the bottom (i.e., the mature 
stable cell type). This is a non-reversible process like water falling down from a 
higher position to a lower. Thus, normally once the cell is committed to one 
valley at bifurcations (or intersections), it cannot go back and enter other(s). 
According to the cell attractor model, induced pluripotent stem cells (iPSCs) 
(55, 56) could be viewed as products of forcing the mature cell types upwards 
from the bottom by external perturbations (by adding Oct3/4, Klf4, Sox2 and c-
Myc) and regain stemness. This forced process drives the mature cells back to 
an intersection in the landscape so that they may enter another valley and switch 
to another cell type; or it may lead them to a normally inaccessible illegitimate 
path, normally not being exploited by evolution, resulting in establishment of a 
malignant cell attractor. This hypothesis is supported by the fact that the process 
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of iPSC derivation shares many characteristics with cancer development and it 
has been reported that premature termination of reprogramming leads to cancer 
development through altered epigenetic regulation (20, 57-59). Tumor cells 
may mimic processes in iPSCs by alterations of key regulating transcription 
factors, which might be an explanation why many tumor cells show stemness.  
Thus, the cell type switch could be achieved by either reversion to a more 
pluripotent state and entering another trajectory (indirect way, Figure 8), or by 
jumping over the ridge between two valleys (direct way, Figure 8) when its 
height seems reduced by mutation in the presence of sufficiently high levels of 
fluctuations or in the response to deterministic regulatory signals (36, 60, 61) 
1.2.3.3 Cancer cell attractors as a tool to understand therapy resistance  
First, according to the model, the inter-cellular heterogeneity is an inherent 
property of any type of cells, due to the fluctuations of the GRN. Secondly, the 
GRN is dynamic, so even within the same cell, its phenotype changes over 
time, within its basin of attraction. Thirdly, as a property of the attractor, there 
is a trend that the cells move to their own attractor and any selected 
subpopulation has the ability to re-establish the whole parental population (36). 
With this in mind anti-cancer treatment cannot efficiently kill all the 
subpopulations of the tumor cell population at the same time. Tumor cells 
which are not killed after treatment have the ability to re-establish the whole 
parental tumor population again, which leads to relapse.  Also, the treatment 
itself could be a potential stress for the tumor cells and enhance  inter-cellular 
heterogeneity(62). Thus, compound screening based on a network view (63), 
and tumor-specific therapy taking into account the cancer cell network concept 
(64) have been discussed. Network medicine, defined as ‘combination drugs 
that interfere with disease network’, has been suggested as a promising future 
direction for therapy (6, 36, 64, 65).  
 
1.3. Epstein-Barr virus biology 
1.3.1 General introduction of EBV  
Epstein-Barr virus (EBV) (also known as Human herpesvirus 4), is a human-
specific gamma-herpes virus. The EBV genome is a double-stranded, 172kb 
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linear DNA molecule (66, 67). It is one of the most common viral infections in 
humans and more than 90% of the adult population worldwide are EBV 
carriers. After primary infection with EBV, humans become EBV carriers for 
life time (68, 69). The primary infection by EBV in early childhood is often 
asymptomatic. Delayed first EBV infection may result in a benign, self-limiting 
disease, called infectious mononucleosis (IM), which is more common in 
developed countries than in developing areas. 
EBV was first discovered in Burkitt lymphoma (BL), a B cell-derived 
lymphoma (70). Soon after its discovery, the in vitro transforming capacity of 
EBV was demonstrated (71). The in vitro EBV transforming system was proven 
to be useful in studies of the viral transforming mechanism and immune 
response against the virus carrying cell. In this thesis, I have exploited 
malignant vs. non-malignant EBV infected cell systems.  
 
1.3.2 EBV latency types in relation to tumors 
Based on the expression pattern of EBV nuclear antigens (EBNA) and latent 
membrane proteins(LMP) and also on the usage of different viral promoters, 
EBV latent infection is classified into latency III, latency II, latent I/0 and Wp-
restricted type (found in some rare BL). EBV infection has been  proposed to be 
an epigenetic driver of tumorigenesis(72), e.g., in gastric cancers(72-74). 
1.3.2.1 Latency III and latency I/0 
Upon in vitro EBV infection of B cells, the virus establishes a latent infection  
and the transformed B lymphocyte will proliferate continuously, giving rise to 
lymphoblastoid cell lines (LCLs)(71). Such LCL expresses six EBNAs (EBNA 
1, EBNA2, EBNA 3 (3A), EBNA 4 (3B), EBNA 6 (3C) and EBNA 5 (-LP)) 
and 3 LMPs (LMP-1, LMP-2A and LMP-2B). This pattern of gene expression 
is referred to as latency III.  In contrast, in latency I, only one virally encoded 
protein, EBNA1 is expressed, occasionally two (LMP2A).  EBNA1 is essential 
for replication and maintenance of the viral episome (75).  The different gene 
expression patterns are achieved by the use of different promoters to generate 
alternative primary transcripts: in latency III LCLs, one of two upstream 
promoters, either Cp or Wp, in the BamHI C or W region of the genome is 
exploited whereas in latency I, EBNA 1 expression is driven by Qp (75). The  
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latency I type does not induce proliferation and its phenotype corresponds to 
non-activated B cells (66). In the asymptomatic EBV persistence in healthy 
carriers, no EBV antigens may be expressed. This is referred as latency 0. 
Latent EBV infection is associated with many kinds of malignancies and 
complication in immunosuppressed patients. Latency III EBV infection is 
associated with post-transplant lymphoproliferative disease (PTLD) (66). The 
latency III  program is expressed only in B lymphocytes and latency III type 
cells can exist only during the acute phase of primary infection, before the EBV 
specific T cell response develops and in patients with impaired immune 
functions, e.g., immunosuppressed stem cell transplanted patients(66).  
Latency I infection associated malignancy includes BL(75). BL seems to arise 
from the malignant transformation of germinal center B cells and it is classified 
into 3 types: the endemic BL (almost 100% EBV positive), the sporadic BL 
(around 30% EBV positive) and AIDS-associated BL (25-40% EBV positive). 
The etiology of BL is associated with EBV infection, but a key event in the 
pathogenesis of BL is a chromosomal translocation on chromosomes 14, 22 or 
2 and the c-myc oncogene on chromosome 8, resulting in deregulated 
expression of the c-myc protein. Alteration in c-myc expression is a 
characteristic of all BL tumors including those that are not EBV associated (75, 
76). It has been shown that MYC contributes to the phenotype of BL cells by 
upregulation of CD10 and CD38 and down regulation of activation markers 
(77).  Although EBV carrying BL patients  are immunocompetent, the BL cells 
can  escape the immune system  surveillance due to that they have only one 
EBV protein, EBNA1 expressed, but no other co-stimulatory surface molecules 
and EBNA 1 does not serve as target for CD8+ CTLs(66).  
In our study, CBM1-Ral-Sto (CBM1), a typical LCL and Rael, derived from 
BL were used to represent the latency I and latency III switch model system. 
The characteristics of the two cell lines are as follows (Figure 9):  
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Figure 9. Comparison of latency III (CBM1) and latency I (Rael) EBV infected cells. 
 
1.3.2.2 Latency II 
EBV latency II cells express EBNA 1, LMP1, LMP 2A and LMP 2B, and are 
associated with the classical Hodgkin lymphoma (HL), nasopharyngeal 
carcinoma (NPC) and nasal NK/T lymphoma. 
1.3.2.3 CD10 and CD54 
CD10 and CD54 are two perfect markers to distinguish latency I and latency III 
cell phenotype. EBV latency I type cells are supposed to be CD10+CD54- and 
latency III cells are CD10-CD54+. 
CD10 (membrane metallo-endopeptidase, MME), is a common acute 
lymphocytic leukemia antigen (CALLA). It is an important cell surface marker 
in the diagnosis of human acute lymphocytic leukemia (ALL). This protein is 
presented on leukemic cells of pre-B phenotype. However, it is not restricted to 
leukemic cells, but also found on a variety of normal tissues. It has been shown 
that CD10 expression relates to differentiation potential and stage(78). 
CD54 (intercellular adhesion molecule-1, ICAM-1) is a cell adhesion molecule 
distributed among normal and neoplastic tissues(79).  It plays a key role in cell-
cell interaction leading to immune response. CD54 is predominantly expressed 
- 
; 
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in the early stages of normal hematopoiesis and during the activation of blood 
cells, and  it is also expressed on neoplastic cells from ‘stem cell derived’ 
neoplasms(79).  
 
1.3.3 EBV load as a biomarker in stem cell transplantation 
1.3.3.1 Overview of stem cell transplantation 
Hematopoietic stem cell transplantation (HSCT) or bone marrow 
transplantation (BMT) is a well-established treatment for hematologic 
malignancies. The survival after the HSCT is expected to be superior compared 
to use of only conventional chemotherapy (80).  Patients receiving bone 
marrow (BMT) or hematologic stem cell transplants (HSCT) show a 
considerable risk to develop EBV-associated post-transplant 
lymphoproliferative disorder (PTLD) and lymphomas, which is a potentially 
fatal disorder associated with the EBV infection (81-83). Relapse and acute 
graft versus host disease (aGVHD) are two other major causes of death of 
patients undergoing HSCT. The most commonly applied strategy for ablative 
therapy in preparation for allogeneic HSCT has been cyclophosphamide 
combined with total body irradiation (TBI) (80, 84). Higher dose of TBI and /or 
chemotherapy could reduce relapse, but increase treatment toxicity, which 
could also be a cause of death. aGVHD is a frequent and at times severe 
inflammatory complication after HSCT. Efforts to diagnose, prevent and treat it 
are important for better survival of the HSCT patients(85). 
1.3.3.2 EBV load together with T cell phenotyping as biomarkers in stem cell 
transplantation 
EBV DNA levels in blood reflect the intricate and complex balance between 
EBV and the host.  EBV load has been proven to be a useful biomarker 
associated with prognosis after HSCT and solid organ transplantation (81, 83, 
86-95). 
After transplantation the levels of EBV DNA-load in blood is affected both by 
immunosuppressive treatment and immune stimulatory mechanisms, like 
aGVHD(83, 91). 
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The importance of T cell mediated immune responses in maintaining balanced 
viral persistence is emphasized by the fact that patients with T cell dysfunction 
are at risk of developing EBV associated PTLD (96, 97). EBV specific T cells 
play an important role in the long term control of the EBV carrier state and it 
has been reported that PTLD may be prevented or even cured by administration 
of donor derived EBV-specific cytotoxic T lymphocytes(81, 82, 98).  
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2 AIMS OF THIS THESIS 
The overall purpose of the studies presented in this thesis was to explore the 
cancer cell attractor using the EBV latent infection model.  
More specifically, the thesis aimed to:  
1. Study the molecular basis for switch between EBV latency I to latency III.  
2. Examine the cell attractor model generated from in silico work and its 
biological relevance by in vitro experimental testing. 
3. Study inter-cellular heterogeneity and cell type maintenance based on the cell 
attractor model. 
4. Characterize the dynamics of cancer cell attractor at single cell resolution. 
5.  Explore the characteristics and fate of edge cells in the cell attractor. 
6. Simulate the cell population dynamics of cell attractors in silico with Fokker-
Planck equation.  
7. Investigate EBV load together with T cell phenotyping and evaluate its 
prognostic value after hematopoietic stem cell transplantation. 
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3 MATERIAL AND METHODS 
I will here primarily discuss the methods which are more specific for my 
studies. Otherwise I do refer to the Methods descriptions in the separate papers. 
3.1 Clinical samples 
The characteristics of the patients are summarized in table 1. Blood samples 
were collected from the patients at 1, 2, 3, 6 and 12 months after HSCT. Fifty-
one patients were included. Seventeen were children (≤ 18 years old) and 34 
were adults. The study was approved by the Stockholm Ethical Committee 
South 2010/760-31/1. In the case of children consent was also obtained from 
parents or legal guardians (on file at Center for Allogeneic Stem Cell 
transplantation, CAST, Karolinska University Hospital, Huddinge). 
3.2 Cell lines 
Six human Epstein-Barr virus (EBV) carrying B-cell lines were used in this 
study: DG75 is an EBV negative Burkitt´s lymphoma cell line(99). Rael is an 
EBV positive Burkitt´s lymphoma (BL) cell line with a latency I expression 
pattern (100). The CBMI-Ral-STO cell line was obtained by in vitro infection 
of cord blood cells with virus rescued from Rael and has a latency III 
expression pattern (101). Mutu I (clone 148) is a BL derived cell line with a 
type I phenotype. Mutu III (clone 99) was obtained by in vitro culturing of 
Mutu I and the cells have a type III phenotype. Akata is an EBV positive BL 
cell line that spontaneously loose EBV forming the EBV negative Akata-N. 
Fresh EBV transformed B cells (fresh LCL) was also applied (Paper III) : 
Resting human B-cells from “buffy coat” or from total blood was purified by 
affinity separation using magnetic microbeads loaded with specific antibodies 
against the B-cell marker CD19 and infected with the B95-8 laboratory strain of 
EBV. 
The cell lines were maintained as suspension cultures in RPMI 1640 medium 
supplemented with 10 % fetal bovine serum (FBS), L-glutamine, streptomycin 
and penicillin.  
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3.3 Single-cell resolution methods 
3.3.1 Flow cytometry (FCM) 
Multi-color FCM was applied to study the heterogeneity of cell surface proteins 
and their dynamics. With this method, expression of more than 12 proteins from 
each cell could be recorded at the same time. One key step in multi-color FCM 
is fluorescence signal compensation. It is required when two or more dyes are 
attached to cells and their ranges of color emission overlaps (spectral overlap). 
The more fluorescence dyes were applied, the more complicated and 
challenging the compensation would be. Fluorescence-activated cell sorting 
(FACS) were applied to select and isolate cells. Based on FCM, Quantum 
MESF (Molecules of Equivalent Soluble Fluorochrome) beads were applied to 
correct for the effect of day-to-day fluctuations of the flow cytometer. The cell 
apoptosis and death analysis was done with APC Annexin V/ Dead Cell 
Apoptosis Kit.  The cell tracing and proliferation analysis was done by CFSE 
staining with the CellTraceTM CFSE Cell Proliferation Kit(102) (paper II, 
paper III). T cell phenotyping was also done by multicolor FCM (paper IV). 
FCM data was analyzed by Flowjo. 
3.3.2 Single cell sequencing 
In this study, the number of edge cells that could be collected is limited, thus, 
we applied single cell analysis. A single cell gene expression profiling, single 
cell tagged reverse transcription (STRT) method, combined with a microfluidic 
sample preparation, Fluidigm C1, was applied. In this STRT-C1 method, a 5 bp 
short random degenerate sequence was introduced to count the single cell 
molecule and remove the amplification bias(103).  
The obtained sequence reads were mapped to a concatenated reference genome 
made up of the human reference genome (UCSF’s Human Genome Assembly 
Release hg19) and ERCC’s synthetic transcript controls using STAR version 
2.3.0 (104). The quality of sample libraries were evaluated for complexity, 
sequencing error rates, reproducibility, exon/intron mapping ratio, 
sense/antisense ratio. For the high quality libraries (at least 10,000 mapped 
reads and 500 detected genes), gene expression levels were computed based on 
uniquely mapped reads in terms of read counts and normalized expression 
calculated in rpm (reads per million mapped reads).  Samples were clustered 
 25 
 
using principal component analysis based on the log-transformed expression 
values and the distances between different sub-samples were computed based 
on the Euclidean distances of the transcriptomes. Genes with significant PCA 
loading were identified using a jackstraws randomization approach (105).  
The computational analyses were done using the STRT pipeline, in-house 
developed python and R scripts. 
3.3.3 Single cell imaging 
Cells isolated by FACS were placed in a30000 well nanochip. After 30 min of 
incubation most of the cells were trapped in the wells and forced to go down by 
gravity. Being distributed randomly most of them where single in a well.  
Minority of wells contained two, three or more cells. Those wells were 
excluded from analysis. The method in detail has been published(106). 
Imaging of the cells in nanochips was performed with Hexascope. (Qantascope 
Biotech,Sweden). 
(http://www.qantascope.com/products/instruments/hexascopehtp).  
3.4 Gene expression profiling by microarray 
Larger amount of RNA was required for microarray analysis, compared to 
single cell STRT-C1 method. In this study, we applied this method together 
with GEDI program to figure out the gene expression patterns of a cell 
population over time to study its dynamics. 
The GEDI maps were generated using the program GEDI 
(http://www.childrenshospital.org/research/ingber/GEDI/gedihome.htm) which 
is applied for visual representation of global gene expression based on self-
organizing maps. In this study, we were more interested to know the whole 
gene expression patterns than to find out differentiated genes, thus, GEDI is a 
useful tool. 
3.5 qPCR analysis 
In this study, qPCR analysis was applied to validate the microarray data (Paper 
II), and also to evaluate the EBV DNA load in HSCT patients (Paper IV).  
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3.6 Malignancy test –agarose cloning 
The loss of contact inhibition and anchorage independence are nature of the 
tumor cells. Normal cells stop to grow due to cell-cell contact in many cases - 
tumor cells do not stop to grow when they meet neighboring cells. This was 
devised to test the breakdown of barriers and anchorage independence - the 
cloning procedure in soft agarose. In our study, we applied this method to test 
if the edge cells from non-malignant LCLs would transiently adopt malignant 
properties or not.  
3.7 In silico modeling 
The in silico modeling based on Fokker-Planck equation (FPE) describes the 
time evolution of a probability density function, PDF, f(X,t) under the 
combined influence of drift (corresponding to deterministic force of relaxation 
to the attractor basin center) and diffusion (corresponding to gene expression 
noise).The observed dynamics of relaxation of the edge cell fractions or the 
population segments  was explored by FPE. The mathematical task was to 
determine the functions A(x) and B(x) in a one-dimensional FPE from 
observations of f(x, t): 
 
Several variations of the basic model have been investigated to exemplify that 
the complex dynamics of cell populations. 
3.8 Statistics 
Overall survival was analyzed using the Kaplan-Meier method and compared 
with the log-rank test. Uni- and multivariate analysis of factors associated to 
survival was performed with the Cox proportional hazards model. Factors with 
a p-value <0.2 in the univariate analysis were included in the backwards 
elimination multivariate analysis. Continuous variables were compared with the 
Mann-Whitney test and categorical variables with the Fisher exact test. 
Analysis was performed with the Statistica software (Statsoft, Tulsa, MN, 
USA). In cell viability analysis, paired student t test was performed to compare 
the differences between groups by GraphPad Prism 6.0. 
  
 27 
 
4 RESULTS AND DISCUSSION 
4.1 Repression of Epstein-Barr virus enhancer Family of Repeats mediated 
transcription by Oct and Grg/TLE transcriptional regulators with 
implications for switching between latency programs (Paper I) 
We consider the switch between latency I and latency III to be crucial in vivo, 
as it controls the proliferative capacity of EBV-infected/-carrying B-cells and 
thus also the level of EBV infected B lymphocytes in blood and lymphoid 
tissues. In normal B cells latency I cells are resting and latency III cells are 
proliferating. We have earlier shown that the switch depends on two viral 
promoters Cp and Qp and their regulatory elements, especially the enhancer for 
Cp designated FR (107). 
In this study, an EBV latency I to latency III switch was proposed: EBNA1 has 
higher affinity to FR than Oct-2 has, so in latency III where the EBNA1 
expression is high and Oct-2 is low, EBNA1 occupy most of the binding sites to 
FR-enhancer, while no or few Oct-2 molecules bind to this DNA sequence and 
as a result the transcription from the C promoter active. In latency I where the 
concentration of Oct-2 is high enough to compete with EBNA1，it will occupy 
the binding sites for EBNA1, and then the protein Grg which converts Oct-2 to 
a repressor binds to Oct-2 and the C promoter is silenced, while “constitutive” 
C promoter takes over (Figure 10). 
 
Figure 10. Latency I to latency III switch model. 
We have earlier validated that Levels of Oct-2 vary between latency I and 
latency III cells: high in latency I and low in latency III, while EBNA 1 shows 
the reverse. We demonstrated that all members of Grg/TLE could repress Oct-2 
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induced promoter activity through FR. This repression could be reversed by 
EBNA1. We suggest that Oct-2 and Grg/TLE-proteins could be involved in 
promoter switching, and as a consequence in latency switch. This switch will in 
turn have dramatic consequences for the fate of the infected B-cell, determining 
whether to proliferate or rest.   
 
4.2 Dynamics inside the cancer cell attractor: cell population heterogeneity, 
stability and escape (Paper II) 
Exploiting EBV latency I cells (Rael cell line, Mutu I, malignant) and a latency 
III system (CBM1 cell line, non-malignant or Mutu III, malignant), we explored 
the cell attractor model and studied its characteristics.  
Protein expression in clonal cell populations showed apparent 
heterogeneity and edge cells dynamically change their marker protein 
expression profile. 
The expression level of surface markers from the Rael and CBM1 showed a 
characteristic bell-shaped histogram with a broad basis. Edge cells, from the tail 
of the histogram, showed their ability to reestablish the parental distribution 
after isolation. They also showed reduced proliferation and viability. Also, 
isolated edge cells of Rael show an mRNA expression profile distinctly 
different from that of parental Rael. 
Our data suggest that edge cells may show ambivalence either transgressing the 
ridge between two basins or returning to their original attractor. In an organized 
microenvironment they might merely not survive. However, with tissue stress 
and disorder, such as during low grade chronic inflammation, they might have a 
larger chance to survive and thus could complete transition to neighboring 
attractors.  This essentially would explain the adoption of malignant, cancer 
stem-cell like phenotypes due to non-genetic plasticity and not mutations, as 
others have suggested (2, 62, 108). 
As from the modelling work of cell attractor and also from our in vitro 
experimental data, the transition of the edge cells to neighboring attractors 
would be an exceptional phenomenon as it would violate the ordered structure 
of cell phenotypes and tissues in a multicellular organism. Indeed, the 
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robustness of attractor states, as described here, suggests that such spontaneous 
transitions are extraordinarily rare.  
Subpopulations representing different levels of marker expression can re-
establish the parental marker distribution upon separate culturing. 
The central finding – directly predicted from the concept of the attractor basin - 
is that any isolated subpopulation derived from the original spectrum of the 
expression levels of a marker can reestablish within days to a few weeks the 
original parental distribution with respect to not just that marker used to define 
the subpopulations but the entire transcriptome. Isolated edge cells reassumed 
properties of cells in the middle of the population distribution, whereas cells at 
the center (mode) of the distribution moved away from the middle towards the 
edges, thus, in both cases “diffusing” (in state space) throughout the entire 
population space. 
One implication is that when the selective pressure of treatment is released, the 
original population can be reestablished by these few temporarily resistant edge 
cells, which may be one explanation for therapy resistance. 
Single cells “move around” in the attractor basin over time. 
We demonstrated that cells in the attractor are not static and they change their 
positon in the attractor dynamically over time. The wide distribution of single 
cells in a cancer cell attractor may result in that some cells in the population are 
resistant to a given drug at a certain time point, but not at another time point 
when they have shifted position in the state space (22, 26, 31, 63, 108, 109).   
Spontaneous shift from one phenotype to another is demonstrated. A key 
regulatory gene can facilitate a switch between attractors. 
Early during switching from Mutu I to III, some Mutu III cells resumed their 
original Mutu I phenotype as revealed by CFSE labelling.  After apparent 
completion of the switch to the Mutu III phenotype, we occasionally detected a 
small subpopulation of CD10highCD54low (type I) cells at variable time 
points. Thus Mutu cells seem to oscillate spontaneously between the two 
“attractors”. 
By knock down Oct2, a small fraction of Rael cells transiently switch from 
CD10+CD54- (type I) to CD10-CD54+ (type III) phenotype. 
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Two virtual forces identified by mathematical modeling of the population 
re-establishment by Fokker-Planck equation. 
The description of the cell population distribution relaxation using a simple FPE 
mathematical model suggests that the dynamics of cell states around a cancer 
cell attractor is reasonably represented by two virtual forces,  a deterministic 
drift force and a diffusion term that captures the stochastic fluctuations due to 
molecular noise that affects gene/protein marker expression.  
 
4.3 Transient phenotypic switch between non-malignant and cancer cell 
attractors (Paper III) 
In line with our exploration of cancer cell attractors on Paper II, we deepened 
the analysis of gene expression profiles (GEP) in small distinct subpopulations 
representing a cross section of the basin of attraction covering both type I and 
type III cells and compared their biological functions.  
We have demonstrated inter-cellular heterogeneity of the clonal cell population 
at protein level by measuring surface markers and at mRNA level by 
microarray in Paper II. Here we now explore the mRNA levels (transcriptome) 
by an RNAseq method designed for single cell analysis. Gene expression 
profiles show that the CD10highCD54low edge cells from CBM1 is a distinct 
population and resemble Rael more than its parental population, CBM1, as 
analyzed by hierarchical clustering based on overall gene expression patterns. 
This was also evident by calculating the Euclidean distance between the edge 
cells to Rael and CBMI, and also between Rael and CBM1 cells, and finally 
also shown by principle component analysis (PCA). Also, longitudinal live 
single-cell imaging was performed to explore cell divisions of the edge cells 
and the capacity to proliferate varied dramatically between each single cell. 
The key biological functions of the most differentiated genes in the CBM1 edge 
cells compared to parental CBM1 and Rael were found out by gene set 
enrichment analysis GSEA. 
The edge cells of CBM1 also show higher cloning frequency in soft agarose. 
While type I BL cells clone well in soft agarose correlating to their malignant 
phenotype, in vitro EBV-transformed  type LCLs show very low cloning 
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frequency, when freshly transformed  0,001 -0,01%. Here we choose to analyze 
recently infected B-cells instead of CBM1, because the long term transformed 
B cells do gradually increase their agarose cloning frequency. Thus, edge cell of 
a fresh LCL made colonies in soft agarose like BL cells do, while the mode 
cells did not. 
In conclusion, our result suggests that the edge cell from a non-malignant cell 
line might adopt some of the characteristics of the cells of a nearby adjacent 
malignant cell attractor without genetic mutations. This will inspire further 
studies on non-genetic intercellular heterogeneity and the possibility that 
tumorigenesis could even initiate without genetic aberrations in the right 
adverse microenvironment.  
 
4.4 Both high and low levels of cellular Epstein-Barr virus DNA in blood 
identify failure after hematologic stem cell transplantation in conjunction 
with acute GVHD and type of conditioning (Paper IV) 
The number of EBV infected B cells in blood of EBV carriers – the EBV load - 
is ultimately a reflection of the control of the switch between latency I (non -
proliferating cells) and latency III (proliferating cells). Exactly how and when 
this switch control operates in vivo is not clear. Most of the cells in the blood of 
healthy persons or in risk groups are of latency 0/I type and thus non-
proliferating. Thus the expansion of the EBV-infected B-cell pool, when 
necessary, takes place elsewhere in vivo, and probably in lymphoid tissues. 
There is a small possibility also that the EBV+ B cells pool can be expanded by 
new infections of cells, probably in lymphoid tissues in the oropharynx where 
there also can be access of infectious virus. 
In a clinical follow-up project we determined EBV load and immune 
parameters in HSCT patients by regular sampling during one year after 
transplantation. 
Grouping according to the EBV load  
The border values between the groups were set based on the EBV load data:   
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Grouping EBV copy number of the three PBMC collected at 
1st,2nd, 3rd month after transplantation (copies/10
6
 
PBMC) 
EBVhigh+low EBVhigh > 90 000 in at least 1/3 samples(s), or > 60 000 in at 
least 2/3 samples 
EBVlow < 6000 in all the 3 samples, or negative in at least 2/3 
samples 
EBVintermediate All the rest samples 
Thirty of the 51 patients (60%) were assigned to the EBVhigh+low group, 
according to our definition. Twenty-one patients (40%) belong to the 
EBVintermediate group. There was no difference in clinical parameters between 
these two groups. 
Overall survival of patients in the two EBV groups,  and risk factors, 
survival and cause of death in the HSCT patients. 
The EBVhigh+low patients had a lower overall survival (OS) rate than those in the 
EBVintermediate group (Figure 1; p =0.03). OS at 5 years was 67% vs 90%, (P < 
0.03). In the combined multivariate analysis three factors were associated to 
mortality: high+low EBV DNA load, acute GVHD II-IV and conditioning with 
TBI ≥6 Gy.  
The causes of death (n=11) in the EBVhigh+low group were specifically relapse 
(n=4), bacterial infection (n=3), organ failure (n=3, one also with bacterial 
infection), acute GVHD (n=1) and a secondary malignancy (n=1, not EBV 
related).  
Dynamics of immune reconstitution in the two EBV load groups 
In fourteen of the patients we performed follow up of cellular immune 
parameters. The analysis included frequency of CD3+ T cells, CD4+ cells, 
CD8+cells, Treg cells (CD3+/CD4+/CD4+CD25hi+/Foxp3+/CD127-) and 
CD4-CD8- cells (double negative, DN). Seven of these patients belonged to the 
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EBVintermediate group and seven to the EBVhigh+low (5 in EBVlow  group and 2 in 
EBVhigh  group). 
While the levels of EBV load inversely related to total CD3 and CD4 levels, as 
for DNs, such a relation was only detected during the first month after HSCT 
but not later. In general, CD8+ and DN cells specific for lytic EBV antigen 
were more frequent than those with specificity to the latent antigen. Two cases 
illustrating different patterns of EBV DNA load in relation to reconstitution of 
EBV specific CD8+ and CD4-CD8- cells were shown in detail in paper IV. Our 
data suggest that cell-bound EBV DNA load is an interesting reflection of the 
quality and balance of reestablishing the immune system. Moderate levels of 
EBV DNA load, reflects a balanced reconstitution, the parameters of which 
now should be better established. 
In conclusion, in this study, we found a strong prognostic value of predefined 
levels of EBV DNA load in HSCT patients. Patients with very low or high 
levels of cell bound EBV-DNA in blood early after transplantation showed a 
poor prognosis, compared to patients with intermediate levels. When combined 
with two other risk factors, severe acute GVHD (aGVHD II-IV) and 
conditioning with high dose total body irradiation (TBI), none of these patients 
survived more than two years after transplantation. Data on EBV load adds a 
significant impact on survival and the patients with the three defined risk-
factors had an extremely poor outcome. EBV load may be a surrogate marker 
for defining patients with dysfunctional immune reconstitution after HSCT. 
Patients groups were small and the study has to be extended to more patients, 
but if true the group with dramatically poor outcome deserves strong attention 
from a clinical handling point of view to improve this poor outcome of the 
intense treatment regime.   
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5 UNSOLVED PROBLEMS AND HYPOTHESES FOR 
FUTURE WORK 
5.1 What does the stronger negative fluorescent signal in FCM mean? 
In FCM, unstained cells and /or isotype control stained cells are applied as a 
negative control for the antibody labeled cells from the same culture. Rael cells 
stained with antibody anti-CD54 conjugated with Pacific blue (Figure 11a, in 
orange), with Pacific blue isotype control (Figure 11a, in blue) and unstained 
Rael parental control (Figure 11a, in black) were shown. The shadowed area 
represented the range of the unstained control and isotype control, and was 
defined as negative. The isotype control has a slightly stronger signal than 
unstained control but the range along the x axis of these two controls was 
almost the same, while anti-CD54 stained Rael was higher. The CD54+ Rael 
cells (those out of the range of the dark area, Figure 11a) were isolated, as 
shown in the blank box of figure 11b, part A. These cells reestablished the 
parental distribution within 7 days after isolation, with the majority (98.4%) of 
the isolated CD54+ cells becoming CD54- again, as we concluded in paper II. 
However, here we also notice that the CD54 negative cells did not distribute 
randomly in the negative area. The CD54 negative cells shift from right to the 
left along the x axis (the direction of CD54 high to low), until the parental 
distribution of CD54 was reestablished. So here is a question we have no 
answer: what does the reestablishment of parental negative distribution mean 
and how come these presumed background signals are detected by FCM? Is 
there any biological meaning of stronger or weaker negative signal in FCM? In 
figure 2E of paper II, to circumvent these questions, we present the data as dots 
instead of the histogram below (the same data, shown in different ways) 
(Figure 11). 
     
Figure 11. Stronger negative fluorescent signals.  
  
a                                                     b 
        CD54-              CD54+ 
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5.2 Subpopulation suicide as a population survival strategy?   
We noticed that the edge cells defined and isolated based on some parameter 
may transiently appear as two distinct subpopulations after isolation, one close 
to the basin of the attractor according to the defining parameter while the other 
is further away. The former one reestablishes the parental distribution while the 
latter gets fewer and fewer, until they disappear completely (Paper II, figure 3B 
and 3C). We have described this phenomenon briefly in the supplementary part 
in paper II (Suppl. 1.1.2).  It appears to be not the result of experimental noise 
or erratic behavior since it was observed in two consecutive days and also in 
several repeated experiments, and both  in cells with both strong and 
weak/negative surface marker expression, although the time point of its 
appearance varied. Here we show another observed example of this 
phenomenon (Figure 12): The isolated CD10 low edge cells showed two 
subpopulations during culture after isolation (Figure 12, in blue): one is of 
lower CD10 level, close to the Rael unstained negative control (Figure 12, in 
orange), which disappeared later, which the other is of higher CD10 level, close 
the Rael CD10 stained parental control, which reestablished the parental 
distribution(Figure 12, in green).  
 
 
Figure 12. CD10 expression levels of Rael CD10lowest edge cells (in blue) cultured after 
isolation, compared with Rael unstained cells (in orange) and Rael CD10 labelled parental 
control (in green).  
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Hypotheses explaining this phenomenon:  
5.2.1. Asymmetric cell division and self-suicide strategy 
One cell obtains abnormal amounts of protein correlating to death while the 
other cell accumulates the proper amount of proteins to reach the range of the 
basin of attraction with higher chance of survival.  
In this hypothesis,  when cells are under extreme situations (in a status far away 
from its basin of attraction), e.g., extremely low or high expression level of 
certain proteins,  beyond the range of its phenotype, which may be caused by 
external stimuli, or internal biological noise, the cells would experience 
asymmetric cell division. By doing so, when the cell population is short of 
biological resources (e.g., surface markers), one cell offers its own limited 
material to the other when dividing and commits suicide itself. (Figure 13). 
 
Figure 13. Asymmetric cell division--- subpopulation suicide strategy. (Modified from 
http://www.vladstudio.com/ipad-wallpapers/?kw=cell)  
 
5.2.2 Delivered among cells or by cell-cell contact 
Another hypothesis to explain this phenomenon would that there is biological 
material transfer between cells in such extreme situations, e.g., using exosomes.  
Or by transfer by cell-cell contact. 
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